Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Collaboration Announcement

11 Apr 2013 16:48

RNS Number : 1786C
Advanced Oncotherapy PLC
11 April 2013
 



ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or "the Company")

 

COLLABORATION ANNOUNCEMENT

 

Advanced Oncotherapy (AVO) is pleased to announce a newly established synergy collaboration between CERN and Application of Detectors and Accelerators to Medicine SA ("ADAM").

 

A team of experts in accelerator and detector technology from CERN founded ADAM with Italian entrepreneur Dr Alberto Colussi in 2007. ADAM aims to capitalise on the know-how and infrastructure that CERN provides to build innovative accelerators for proton therapy and for conventional radiotherapy.

 

ADAM's research and development activities have focused on two main fields: the design and construction of compact linear accelerators for conventional radiotherapy, and of compact linear accelerators for proton therapy. The next phase of the collaboration, a newly established synergy between ADAM, CERN and AVO will complete the Proton Beam accelerator complex.

 

"For CERN the transfer of technology and know-how in the medical field is an important part of the impact of basic science on societal issues," says CERN Director of Accelerators and Technology Steve Myers. "This partnership is a pragmatic way to share our competences and know-how with industrial partners who are able to bring this innovative medical solution to the market."

 

 

For further information, please contact:

 

Michael Sinclair,

Chief Executive

Sandy Jamieson

Jon Levinson

Simon Hudson,

Advanced Oncotherapy Group Plc

Libertas Capital Corporate Finance Ltd

Peterhouse Corporate Finance

Tavistock Communications

0203 617 8739

(NOMAD & Joint Broker)

(Joint Broker)

(Financial PR & IR)

020 7569 9650

020 7469 0930

020 7920 3150

 

 

 

About Advanced Oncotherapy

 

Advanced Oncotherapy is a provider of new technology for innovative and patient-focused cancer treatments. These are technologies endorsed internationally by UK and global cancer clinicians, but not currently available in the NHS nor the private sector. Such initiatives build on the Group's 28.75% stake in Advanced Proton Solutions (Holdings) Ltd and its Oncotherapy Resources business focused on non-melanoma skin cancer and early stage breast cancer. Advanced Proton Solutions is pioneering the use of Proton Beam Therapy in the UK. They have secured planning approval for its first proton beam therapy center in the UK in the City of London. In 2011, over 70,000 patients were treated worldwide with proton beam therapy in 32 centres.

 

-ends-

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRABUGDSRSBBGXB
Date   Source Headline
30th Oct 20205:00 pmRNSTotal Voting Rights
26th Oct 20207:00 amRNSEquity fundraise of c.£7.7m
23rd Oct 20202:25 pmEQSHardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy: Progress towards commissioning of first LIGHT
19th Oct 20207:00 amRNSInvestor Day Update
8th Oct 20202:06 pmRNSSecond Price Monitoring Extn
8th Oct 20202:00 pmRNSPrice Monitoring Extension
7th Oct 202010:50 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Progress towards commissioning of first LIGHT
6th Oct 20207:00 amRNSReplacement: Grant of LTIP Options
5th Oct 20207:01 amRNSNotice of Investor Day
5th Oct 20207:00 amRNSGrant of LTIP Options
29th Sep 20207:00 amRNSDirectorate Appointment
29th Sep 20207:00 amRNSInterim Results
8th Sep 20207:00 amRNSTechnical Development Update
7th Sep 20207:00 amRNSAppointment of Joint Broker
21st Aug 20207:00 amRNSDraw down from Nerano Pharma debt facility
18th Aug 20204:30 pmRNSDirector/PDMR Shareholding
29th Jul 20202:52 pmRNSResult of AGM and Directorate Changes
2nd Jul 20207:15 amEQSHardman & Co Research : Advanced Oncotherapy (AVO): End-goal fast approaching
29th Jun 20207:01 amRNSFinal Results for the year ended 31 December 2019
29th Jun 20207:00 amRNSStrategic funding partnership and debt facility
17th Jun 20207:00 amRNSHolding(s) in Company
8th Jun 20207:00 amRNSDirectorate Changes and Notice of Results
3rd Jun 20205:30 pmRNSHolding(s) in Company
29th May 20205:00 pmRNSTotal Voting Rights
20th May 20204:30 pmRNSHolding(s) in Company
11th May 20206:01 pmRNSResult of General Meeting, Additional Subscription
21st Apr 20207:00 amRNSNotice of GM and Posting of Circular
9th Apr 20207:30 amRNSFurther re Subscription and Issue of Equity
9th Apr 20207:00 amRNSProposed Subscription to raise c.£15 million
26th Feb 20203:40 pmEQSHardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum
20th Feb 20207:00 amRNSUHB and AVO to collaborate over LIGHT system
20th Feb 20207:00 amRNSUHB and AVO to collaborate over LIGHT system
17th Feb 202011:45 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum
17th Feb 20207:00 amRNSPurchase of a LIGHT proton therapy system
11th Feb 20207:00 amRNSPartnership with The London Clinic
4th Dec 20197:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Proving the accuracy and superiority of minibeams
4th Dec 20197:00 amRNSTwo-Year Collaborative Research Study
3rd Dec 20195:45 pmRNSHolding(s) in Company
29th Nov 20195:00 pmRNSTotal Voting Rights
28th Nov 201910:15 amRNSHolding(s) in Company
20th Nov 20197:00 amRNSSubscription to raise c.GBP 2.7 million
11th Nov 20199:11 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): FLASH benefits from new US reimbursement
6th Nov 20193:35 pmRNSTotal Voting Rights
10th Oct 20197:00 amRNSChange of Broker
30th Sep 20195:15 pmRNSTotal Voting Rights
30th Sep 20197:00 amRNSFurther re funding for first LIGHT system
30th Sep 20197:00 amRNSHalf-year Report
9th Sep 20194:48 pmRNSExercise of Warrants and Issue of Equity
30th Aug 20195:00 pmRNSTotal Voting Rights
29th Aug 20192:06 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.